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Abstract
OBJECTIVES: The aim of this 12-week Phase IIb study was to assess the efficacy
and safety of olokizumab (OKZ), a humanised anti-IL6 monoclonal antibody, in
patients with rheumatoid arthritis (RA) with moderate-to-severe disease activity
who had previously failed tumour necrosis factor (TNF) inhibitor therapy. The
dose-exposure-response relationship for OKZ was also investigated. METHODS:
Patients were randomised to one of nine treatment arms receiving placebo (PBO)
or OKZ (60, 120 or 240 mg) every 4 weeks (Q4W) or every 2 weeks (Q2W),
or 8 mg/kg tocilizumab (TCZ) Q4W. The primary endpoint was change from
baseline in DAS28(C-reactive protein, CRP) at Week 12. Secondary efficacy
endpoints were American College of Rheumatology 20 (ACR20), ACR50 and
ACR70 response rates at Week 12. Exploratory analyses included comparisons
of OKZ efficacy with TCZ. RESULTS: Across 221 randomised patients, OKZ
treatment produced significantly greater reductions in DAS28(CRP) from baseline
levels a...
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ABSTRACT
Objectives The aim of this 12-week Phase IIb study
was to assess the efﬁcacy and safety of olokizumab
(OKZ), a humanised anti-IL6 monoclonal antibody, in
patients with rheumatoid arthritis (RA) with moderate-to-
severe disease activity who had previously failed tumour
necrosis factor (TNF) inhibitor therapy. The dose-
exposure-response relationship for OKZ was also
investigated.
Methods Patients were randomised to one of nine
treatment arms receiving placebo (PBO) or OKZ (60, 120
or 240 mg) every 4 weeks (Q4W) or every 2 weeks
(Q2W), or 8 mg/kg tocilizumab (TCZ) Q4W. The primary
endpoint was change from baseline in DAS28(C-reactive
protein, CRP) at Week 12. Secondary efﬁcacy endpoints
were American College of Rheumatology 20 (ACR20),
ACR50 and ACR70 response rates at Week 12.
Exploratory analyses included comparisons of OKZ
efﬁcacy with TCZ.
Results Across 221 randomised patients, OKZ
treatment produced signiﬁcantly greater reductions in
DAS28(CRP) from baseline levels at Week 12, compared
to PBO (p<0.001), at all the OKZ doses tested (60 mg
OKZ p=0.0001, 120 and 240 mg OKZ p<0.0001).
Additionally, ACR20 and ACR50 responses were
numerically higher for OKZ than PBO (ACR20:
PBO=17.1–29.9%, OKZ=32.5–60.7%; ACR50:
PBO=1.3–4.9%, OKZ=11.5–33.2%). OKZ treatment, at
several doses, demonstrated similar efﬁcacy to TCZ
across multiple endpoints. Most adverse events were
mild or moderate and comparable between OKZ and
TCZ treatment groups. Pharmacokinetic/
pharmacodynamic modelling demonstrated a shallow
dose/exposure response relationship in terms of
percentage of patients with DAS28(CRP) <2.6.
Conclusions OKZ produced signiﬁcantly greater
reductions in DAS28(CRP) from baseline at Week 12
compared with PBO. Reported AEs were consistent with
the safety proﬁle expected of this class of drug, with no
new safety signals identiﬁed.
Trial register number: NCT01242488.
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic, systemic
autoimmune disease which can lead to destruction
and physical dysfunction of joints resulting in a
signiﬁcant increase in morbidity and mortality.1 For
patients who have an inadequate response to
DMARDs, tumour necrosis factor (TNF) inhibitors
are frequently added, usually in combination with
methotrexate (MTX).2 Approximately 40–50% of
patients receiving TNF inhibitors, however, also
have an inadequate response to this treatment.3–5
Therapeutic approaches using alternative mechan-
isms of action are therefore an important unmet
need for this patient population.
An alternate therapeutic target is the
pro-inﬂammatory cytokine interleukin-6 (IL-6).
IL-6 is an important mediator of inﬂammation and
is involved in key immunologic processes underlying
the pathology of RA, such as T-cell activation and
B-cell proliferation, as well as osteoclast differenti-
ation.6 The amount of IL-6 present in the synovial
ﬂuid of patients with RA has been shown to correl-
ate with the severity of synovitis and joint destruc-
tion.7–9 An anti-IL-6 receptor (IL-6R) antibody,
tocilizumab (TCZ), has been approved for the treat-
ment of RA.10–17 TCZ is a humanised monoclonal
antibody that binds to the IL-6 receptor.18
Olokizumab (OKZ, CDP6038), a humanised
monoclonal antibody speciﬁc for the IL-6 cytokine,
is currently in development for the treatment of
RA. It targets the IL-6 cytokine rather than the
receptor, and selectively blocks the ﬁnal assembly
of the signalling complex. In Phase I (healthy
volunteers) and IIa (patients with RA on MTX)
clinical trials, OKZ was well tolerated after intra-
venous and subcutaneous delivery with a median
plasma half-life of approximately 31 days, 76% bio-
availability and no apparent antidrug antibody-
mediated clearance.19 OKZ also markedly reduced
free IL-6 levels and suppressed C-reactive protein
(CRP) up to 12 weeks after single-dose subcutane-
ous administration in patients with RA.20
The primary aims of this Phase IIb, dose-ranging
study were to evaluate the efﬁcacy and safety of
OKZ in an active RA population who had previ-
ously failed TNF inhibitor therapy.
MATERIALS AND METHODS
Study design
This was a 12-week, Phase IIb, dose-ranging,
double-blind, placebo (PBO) and active-controlled,
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multicenter, randomised study (NCT01242488), conducted
between November 2010 and June 2012, to evaluate the efﬁ-
cacy and safety of subcutaneous OKZ in patients with moder-
ately to severely active RA who had previously failed TNF
inhibitor therapy. The study protocol was approved by the
Institutional Review Board/Independent Ethics Committee as
deﬁned in local regulations and performed according to the
Declaration of Helsinki. All patients provided written consent.
The primary objective of the study was to evaluate the efﬁ-
cacy of OKZ at different doses and administration frequencies
compared with PBO. Secondary objectives were to evaluate the
safety, pharmacokinetics (PK), pharmacodynamics (PD) and
immunogenicity of repeated doses of OKZ, and to assess the
dose-response and exposure-response relationship of OKZ with
efﬁcacy. An exploratory endpoint was to compare the efﬁcacy
and safety of OKZ with TCZ.
Of the 398 patients enrolled in the study, 221 were rando-
mised to 1 of 9 treatment arms (ﬁgure 1). Randomisation was
performed centrally using an interactive voice-response system.
Patients received either PBO or OKZ (60, 120 or 240 mg) every
4 weeks (Q4W) or every 2 weeks (Q2W), or 8 mg/kg TCZ
Q4W. Doses were selected in order to cover 35–75% of the
maximal anticipated effect on DAS28(erythrocyte sedimentation
rate, ESR) at 12 weeks, or 45–85% of the maximal anticipated
effect at 24 weeks, based on PK/PD analysis of previous study
data.19 20
Randomisation was stratiﬁed according to the number of
prior failed TNF inhibitors (1 vs 2 or more). Two safety
follow-up visits were undertaken 6 and 12 weeks after the last
study dose. To maintain blinding of the treatment, all patients
received an intravenous infusion Q4Wand two 1.2 mL subcuta-
neous injections Q2W. TCZ dose is the approved dose in
Europe by the EMA,21 and the highest dose approved by the US
Food and Drug Administration (FDA).18
Patients who completed the study were eligible to receive
OKZ in an open-label extension study (NCT01296711).
Patients
This study population were individuals with active RA and an
inadequate response to MTX, and at least one previous
anti-TNF therapy. Patients were ≥18 years old, with adult-onset
RA of at least 6 months duration (1987 American College of
Rheumatology (ACR) classiﬁcation criteria22) or a score of ≥6
by the ACR/European League Against Rheumatism (EULAR)
Classiﬁcation and Diagnostic Criteria for RA.23 Eligible patients
had tender joint count ≥6 (TJC; assessment of 68 joints) and
swollen joint count ≥6 (SJC; assessment of 66 joints) and CRP
≥1.2 times the upper limit of normal (ULN), or ESR >28 mm/
h. Patients were required to be on a stable dose of MTX and
continued current steroids and NSAIDs.
Major exclusion criteria included diagnoses of other inﬂamma-
tory arthritis or a non-inﬂammatory type of arthritis that inter-
fered with efﬁcacy evaluations, functional capacity Steinbrocker
Class IV,24 and prior exposure to IL-6 inhibitors. Patients were not
permitted to use DMARDs other than MTX within 12 weeks
prior to screening (unless undertaking appropriate washout).
Patients with a known risk of severe or major infections, or ele-
vated levels at screening of creatinine, alanine aminotransferase
(ALT) or aspartate aminotransferase (AST), or reduced platelets,
white blood cell count or neutrophil count were excluded.
Efﬁcacy analyses
Efﬁcacy outcomes were assessed in the Full Analysis Set (FAS),
consisting of all randomised patients who received at least one
Figure 1 Patient disposition.
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dose of study medication and had at least one post-baseline efﬁ-
cacy measurement.
The primary efﬁcacy endpoint was the change from baseline
in DAS28(CRP) at Week 12. Secondary efﬁcacy endpoints were
ACR20, ACR50 and ACR70 at Week 12 for OKZ and PBO.
Major exploratory analyses included: ACR20/50/70 response
rates (at Weeks 1, 2, 4, 6, 8, 10 and 12), % of patients with
DAS28(CRP) <2.6 at Weeks 2, 4, 8 and 12), TJC, SJC, Clinical
Disease Activity Index (CDAI) and the Health Assessment
Questionnaire-Disability Index (HAQ-DI).
Safety
Safety assessments included measurement of vital signs and
laboratory parameters as well as recording of
treatment-emergent adverse events (TEAEs) and serious TEAEs.
Safety variables were analysed using the Safety Set (SS) (all
patients who received at least 1 dose, or partial dose, of study
medication).
Statistical analyses
Unless speciﬁcally stated, FAS was used for all analyses. DAS28
(CRP) was analysed using a mixed effects model for repeated
measures (MMRM). ACR20/50/70 responder rates were esti-
mated using generalised estimating equation (GEE) method-
ology with Multiple Imputation (MI). Missing data for SJC/
TJC/HAQ-DI/CDAI change from baseline were imputed using
last observation carried forward (LOCF). Non-responder imput-
ation was used for analysis of % patients with DAS28(CRP)
<2.6 to control for missing values. The number of prior failed
TNF inhibitors was included as a categorical covariate in all stat-
istical analyses. Unless otherwise stated, all statistical tests were
two-sided.
Power and sample size calculations were based upon simula-
tions for change from baseline in DAS28 at all assessed postba-
seline visits, using the MMRM method speciﬁed for the
primary efﬁcacy analysis.
Pharmacokinetic/pharmacodynamic analyses
Blood samples for determination of plasma OKZ, TCZ and
anti-OKZ antibodies were collected at baseline and at each sub-
sequent visit. Non-linear mixed modelling was employed for
the analysis of the OKZ PK data. The ﬁnal population PK
model was used to derive individual concentration or exposure
measures for use in the PK/PD analyses which involved describ-
ing the relationship between PK measures and multiple efﬁcacy
and safety endpoints via mixed effects methodology.
RESULTS
Baseline characteristics and patient disposition
Figure 1 details the patient disposition; 89.6% of randomised
patients completed the 12-week treatment phase. Patient demo-
graphics across the treatment groups were similar and represen-
tative of patients with RA with long-standing, active disease
(table 1). Most patients were using MTX at baseline (95% of
patients). The most common previous TNF inhibitors were eta-
nercept (50.7%), adalimumab (45.2%) and inﬂiximab (36.5%);
certolizumab pegol and golimumab had each been previously
used by 13.7% of patients. More than 40% of patients had
failed to respond to at least two TNF inhibitors. Previous
non-TNF-targeting biologics used included abatacept (16.0%)
and rituximab (11.0%). At recruitment, 107 patients (48.9%)
met the inclusion criteria for ESR (>28 mm/h) and CRP (≥1.2
ULN); 89 (40.6%) and 21 (9.6%) patients met only the criteria
for ESR or CRP, respectively.
Clinical efﬁcacy
Change from baseline in DAS28(CRP)
Across all dose groups, treatment with OKZ resulted in a
greater improvement in DAS28(CRP) mean change from base-
line at Week 12 compared with PBO (table 2), with the greatest
improvement observed in the OKZ 240 mg Q2W group.
Decreases in DAS28(CRP) from baseline were seen from Week
1 (ﬁgure 2A). For every treatment dose, DAS28(CRP) change
from baseline was signiﬁcantly different to the PBO group (for
60 mg OKZ p=0.0001, for 120 and 240 mg OKZ p<0.0001),
as were the overall dose response trends across both dosing fre-
quencies (p<0.0001) (ﬁgure 2B). Comparisons of dosing fre-
quency (Q2W vs Q4W) and dose-by-dose frequency
interactions (Q2W trend vs Q4W trend) were not signiﬁcant
(p=0.6927 and p=0.9912, respectively). The improvements
from baseline in DAS28(CRP) observed in several OKZ treat-
ment groups were comparable to those seen in the TCZ treat-
ment group (table 2). No signiﬁcant response differences were
seen between patients who had previously failed treatment with
1, 2 or >2 TNF inhibitors.
Posthoc analysis revealed that at low OKZ doses, a greater
response was seen in patients with CRP ≥1.2 ULN compared to
all other patients (for OKZ 60 mg Q4W patients mean changes
from baseline at Week 12 were −2.47 and −0.98, respectively).
This was not apparent at higher dose levels (−1.87 and −2.08
for OKZ 240 mg Q2W patients).
ACR20, ACR50 and ACR70 response rates
The ACR20 and ACR50 response rates were higher in OKZ-
treated patients than those receiving PBO at Week 12 (table 2).
This study was not powered to detect signiﬁcant differences in
ACR20/50/70 response rates. However, responses were numeric-
ally higher for ACR20 (p=0.0636) and ACR50 (p=0.0574)
than PBO (table 2). Improvements in ACR20 and ACR50 were
rapid, with increased responses over PBO observed from as
early as Week 1 and Week 4, respectively, and were generally
maintained or increased throughout the treatment
period (ﬁgure 2C,D). These responses were similar for the TCZ
treatment group. Seven patients in OKZ treatment groups and
four patients on TCZ were observed ACR70 responders at
Week 12.
Additional efﬁcacy endpoints
Exploratory analysis of additional efﬁcacy endpoints revealed
improvements in OKZ-treated patients at Week 12 in physical
function (as assessed by HAQ-DI) compared with the PBO
groups, as well as greater reductions in TJC, SJC and CDAI
(table 2). Additionally, a higher percentage of patients demon-
strated DAS28(CRP) <2.6 or DAS28(CRP) ≤3.2 following
treatment with OKZ than PBO. The percentage of patients dem-
onstrating DAS28(CRP) <2.6 in the OKZ 240 mg Q2W group
was more than ﬁvefold higher than that in the PBO Q2W group
(26.1% and 4.5%, respectively). Posthoc analysis showed that at
Week 12, low disease activity (CDAI ≤10.0) was achieved by
patients from all treatment groups, including PBO, with a
higher proportion of patients demonstrating this in the OKZ
120 mg and 240 mg dose groups than the OKZ 60 mg and PBO
groups (table 2). Five of 132 patients in OKZ treatment groups
(from 5 different cohorts), and 5 of 43 patients on TCZ
achieved CDAI remission (CDAI ≤2.8) at Week 12; compared
with none of the 22 patients in PBO groups.
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Table 1 Baseline patient demographics and disease characteristics (full analysis set)
PBO
Q2W (N=22)
OKZ
60 mg
Q2W (N=20)
OKZ
120 mg
Q2W (N=22)
OKZ
240 mg
Q2W (N=23)
PBO
Q4W (N=22)
OKZ
60 mg
Q4W (N=22)
OKZ
120 mg Q4W
(N=23)
OKZ
240 mg Q4W
(N=22)
TCZ
8 mg/kg
Q4W (N=43)
All patients
(N=219)
Population demographic
Age, mean years 59.36 55.50 53.09 55.48 58.18 52.64 53.52 54.55 56.58 55.53
Female, % 86.4 80.0 86.4 91.3 77.3 90.9 87.0 77.3 86.0 84.9
Prior and concomitant medication
Prior failed TNF-inhibitor, n (%)
1 12 (54.5) 14 (70.0) 12 (54.5) 14 (60.9) 12 (54.5) 12 (54.5) 12 (52.2) 13 (59.1) 25 (58.1) 126 (57.5)
≥2 10 (45.5) 6 (30.0) 10 (45.5) 9 (39.1) 10 (45.5) 10 (45.5) 11 (47.8) 9 (40.9) 18 (41.9) 93 (42.5)
Concomitant MTX, n (%) 20 (90.9) 19 (95.0) 20 (90.9) 22 (95.7) 21 (95.5) 21 (95.5) 22 (95.7) 21 (95.5) 42 (97.7) 208 (95.0)
Baseline disease characteristics
Disease duration, median years 10.56 12.30 8.07 8.22 7.45 10.89 11.58 7.83 10.55 9.99
CRP >15 mg/L, n (%) 5 (22.7) 4 (20.0) 6 (27.3) 8 (34.8) 7 (31.8) 7 (31.8) 7 (30.4) 6 (27.3) 16 (37.2) 66 (30.1)
DAS28(CRP), mean 5.53 5.57 5.96 5.94 5.69 6.14 5.61 5.83 5.72 5.77
DAS28(CRP) >5.1, n (%) 14 (63.6) 14 (70.0) 15 (68.2) 18 (78.3) 16 (72.7) 19 (86.4) 16 (69.6) 14 (63.6) 33 (76.7) 159 (72.6)
TJC, median (min-max) 32.74 (9.3–56.7) 18.50 (9.0–68.0) 26.50 (8.0–62.0) 33.00 (6.0–51.0) 22.00 (8.0–58.0) 36.00 (9.0–68.0) 29.29 (7.0–57.0) 25.86 (11.0–59.8) 25.00 (4.0–66.0) 27.00 (4.0–68.0)
SJC, median (min-max) 12.00 (6.0–30.0) 16.50 (6.0–50.0) 14.50 (6.0–58.0) 18.86 (7.0–41.6) 13.17 (4.0–44.7) 21.50 (6.0–58.0) 13.00 (5.2–36.7) 14.50 (6.0–38.9) 12.38 (6.0–32.0) 14.00 (4.0–58.0)
CDAI, median (min-max) 36.83 (20.7–53.9) 36.28 (22.2–66.3) 42.90 (20.2–71.2) 45.20 (18.1–64.3) 36.25 (19.0–60.0) 46.60 (21.4–69.2) 39.92 (14.3–59.7) 40.50 (24.2–59.2) 35.65 (17.7–62.5) 38.90 (14.3–71.2)
HAQ-DI, median (min-max) 1.56 (0.3–2.6) 1.63 (0.5–2.1) 1.44 (0.6–3.0) 1.75 (0.6–2.6) 1.38 (0.0–2.4) 1.81 (0.1–2.9) 1.50 (0.3–2.9) 1.69 (0.0–2.8) 1.63 (0.0–2.9) 1.63 (0.0–3.0)
CDAI, Clinical Disease Activity Index; CRP, C-reactive protein; DAS28, Disease Activity Score 28-joint count; HAQ-DI, HAQ (Health Assessment Questionnaire) Disability Index; MTX, methotrexate; OKZ, Olokizumab; PBO, placebo; SJC, swollen joint count;
TCZ, Tocilizumab; TJC, tender joint count; TNF, tumour necrosis factor.
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Pharmacokinetic/pharmacodynamic analyses
The OKZ plasma concentration-time data were adequately
described by a two-compartment, ﬁrst-order absorption, linear
elimination model. The OKZ PK characteristics were consistent
with those in healthy and mild-to-moderate patients with
RA.19 20 The overall estimate of bioavailability across the Phase I,
IIa and IIb studies was 63.3% (% relative standard error=4.9%).
PK/PD (DAS28(CRP)) data were adequately described by an
indirect concentration-effect sigmoid Emax model, with inhibition
of DAS28(CRP) production. Simulations performed with the
resulting model, extrapolated to Week 24, highlighted the exist-
ence of a shallow dose/exposure response relationship (in terms of
percentage of patients with DAS28(CRP)<2.6, see online supple-
mentary ﬁgure S1). A successful description of the ACR20 data
and its correlation with exposure, taking into account drop-out
using a logistic model, was also possible. By contrast with DAS28
(CRP), simulations exploring the dose-response surface for
ACR20 revealed a steep response curve.
Immunogenicity
Analysis of plasma samples for anti-OKZ antibodies was con-
ducted. Using a study-speciﬁc cut-off, based on blinded analysis
of drug-naive baseline samples, 13 patients (9.8%) in
OKZ-treated groups were anti-OKZ antibody positive.
Importantly, four of these patients were pre-dose positive, and
only one of them displayed a PK proﬁle characteristic of drug-
clearing immunogenicity. Furthermore, ﬁve patients in the
PBO groups (11.3%) and two patients in the TCZ group
(9.8%) were also anti-OKZ antibody positive. Non-speciﬁc
interference by pre-existing immunoglobulins in patients’
plasma has been previously reported25 26 and was shown to
be the case for some of these nominally positive samples with
a posthoc analysis. Thus, the true incidence of speciﬁc
anti-OKZ antibodies is likely to be less than nominally deter-
mined. Details of the immunogenicity investigations and the
efﬁcacy response of the 13 patients who were found nomin-
ally anti-OKZ antibody positive can be found in online
supplementary material (table S1).
Safety (SS)
There were similar numbers of TEAEs reported in the OKZ and
TCZ active dose groups, and the PBO group (range across OKZ
treatment groups: 63.6–87.0%; PBO: 77.3–86.4%; TCZ:
86.0%) (table 3). The majority of TEAEs in all treatment groups
were mild in intensity. Most frequently reported TEAEs (occur-
ring in ≥10% of patients in any treatment group) consisted of
diarrhoea, headache, injection site reactions (PBO: 18.2%;
OKZ: 17.4–47.8%; TCZ: 20.9%), and infections including
upper respiratory tract infections, urinary tract infections and
nasopharyngitis (PBO: 31.8–50.0%; OKZ: 25.0–36.4%). There
Table 2 Efficacy outcomes at week 12 (full analysis set)
Efficacy endpoint
Dosing
frequency
PBO OKZ
60 mg
OKZ
120 mg
OKZ
240 mg
TCZ
8 mg/kg
ΔDAS28(CRP),* LS mean (SE) Q2W −0.78 (0.26) −1.16 (0.28) −1.88 (0.26) −2.01 (0.25) –
Q4W −0.19 (0.26) −1.91 (0.28) −1.84 (0.26) −1.63 (0.25) −2.01 (0.19)
DAS28(CRP)≤3.2,%† Q2W 13.6 20.0 22.7 30.4 –
Q4W 4.5 18.2 30.4 27.3 30.2
DAS28(CRP)<2.6,%† Q2W 4.5 10.0 13.6 26.1 –
Q4W 0.0 13.6 21.7 9.1 20.9
ΔDAS28(ESR),* LS mean (SE) Q2W −0.65 (0.25) −1.53 (0.27) −2.05 (0.25) −1.80 (0.25) –
Q4W −0.16 (0.25) −2.04 (0.26) −1.57 (0.26) −1.59 (0.25) −1.79 (0.18)
ACR20, estimated response %
(95% CI)‡
Q2W 29.9 (15.3 to 50.2) 49.7 (31.0 to 68.5) 55.5 (36.9 to 72.7) 55.5 (37.1 to 72.4) –
Q4W 17.1 (7.3 to 35.0) 60.7 (41.4 to 77.1) 58.4 (39.5 to 75.1) 32.5 (18.1 to 51.2) 68.3 (53.0 to 80.5)
ACR50, estimated response %
(95% CI)‡
Q2W 4.9 (0.7 to 28.0) 19.1 (7.6 to 40.4) 24.9 (11.4 to 46.2) 31.9 (16.0 to 53.5) –
Q4W 1.3 (0.1 to 14.4) 33.2 (16.8 to 55.0) 21.3 (9.0 to 42.8) 11.5 (4.2 to 27.7) 27.7 (15.4 to 44.8)
ACR20, observed response
n (%)†
Q2W 7 (33.3) 6 (35.3) 10 (50.0) 11 (52.4) –
Q4W 1 (5.0) 12 (75.0) 11 (61.1) 7 (33.3) 27 (65.9)
ACR50, observed response
n (%)†
Q2W 1 (4.8) 3 (17.6) 5 (25.0) 5 (23.8) –
Q4W 0 6 (37.5) 3 (16.7) 3 (14.3) 10 (24.4)
ΔCDAI,* Q2W −8.95 (−41.5, 13.8) −8.00 (−36.4, 19.0) −14.65 (−57.9, 14.3) −16.30 (−58.2, 8.9) –
Median (min, max) Q4W −3.03 (−44.1, 23.8) −18.51 (−69.2, 48.0) −19.09 (−35.2, 8.8) −12.99 (−42.9, 4.0) −17.30 (−49.2, 15.1)
CDAI≤10.0, estimated
response % (95% CI)§,¶
Q2W 13.6 (4.5 to 34.8) 9.9 (2.5 to 32.3) 22.7 (9.8 to 44.3) 30.3 (15.1 to 51.5) –
Q4W 9.1 (2.3 to 29.9) 9.1 (2.3 to 29.9) 30.4 (15.2 to 51.5) 13.6 (4.4 to 34.7) 27.8 (16.5 to 42.9)
CDAI≤10.0, observed
response n (%)¶
Q2W 3 (13.6) 2 (10.0) 5 (22.7) 7 (30.4) –
Q4W 2 (9.1) 2 (9.1) 7 (30.4) 3 (13.6) 12 (27.9)
ΔHAQ-DI,* median (min, max) Q2W 0.00 (−1.0, 0.6) −0.25 (−1.0, 0.9) −0.25 (−0.9, 1.4) −0.38 (−1.6, 0.1) –
Q4W 0.06 (−1.0, 2.1) −0.50 (−1.6, −0.1) −0.25 (−1.5, 0.4) 0.00 (−1.0, 0.5) −0.25 (−1.5, 0.3)
ΔTJC,* median (min, max) Q2W −10.00 (−46.0, 33.0) −8.00 (−34.0, 5.0) −10.00 (−55.0, 3.2) −10.30 (−48.0, 13.0) –
Q4W −3.00 (−49.0, 18.3) −18.00 (−68.0, 7.7) −15.00 (−29.0, 12.0) −8.50 (−18.3, 7.0) −11.00 (−46.0, 8.0)
ΔSJC,* median (min, max) Q2W −3.00 (−18.0, 22.3) −7.00 (−26.0, 4.0) −7.00 (−55.0, 7.0) −10.00 (−41.6, 7.0) –
Q4W −3.00 (−37.0, 22.0) −11.00 (−51.0, 19.0) −9.89 (−21.0, 15.0) −8.25 (−22.3, 22.0) −7.45 (−29.5, 11.0)
*change (Δ) from baseline, MMRM analysis.
†observed rate.
‡estimate from the GEE-MI model.
§estimate from the Logistic Regression (non-response imputation) model.
¶results of posthoc analysis.
ACR, American College of Rheumatology; CDAI, Clinical Disease Activity Index; CRP, C-reactive protein; DAS28, Disease Activity Score 28-joint count; ESR, erythrocyte sedimentation
rate; GEE, generalised estimating equation; HAQ-DI, HAQ (Health Assessment Questionnaire) Disability Index; LDA, low disease activity; LS, least squares; MI, multiple imputation;
MMRM, mixed effects model for repeated measures; OKZ, olokizumab; PBO, placebo; SJC, swollen joint count; TCZ, Tocilizumab; TJC, tender joint count.
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were no incidences of diverticulitis and no gastrointestinal (GI)
perforations reported. All TEAEs are reported to Week 12, and
thus represent short-term safety outcomes.
The incidence of serious TEAEs was similar between treat-
ment groups, and no serious TEAE was reported by >1 patient
(table 3). In the OKZ treatment groups, serious TEAEs reported
were chest pain, pneumonia, perineal abscess, abnormal liver
function test (LFT), back pain, basal cell carcinoma and mania.
One serious pneumonia case was reported in the TCZ treatment
arm (2.3% patients); other serious TEAEs in the TCZ group
included increased blood triglycerides and limb abscess (2.3%
patients, respectively). There were no deaths throughout the
study.
Laboratory abnormalities included elevated levels of ALT,
AST and gamma glutamyl transferase (GGT), as well as
decreased neutrophil counts and increased blood cholesterol
(table 4). In the OKZ treatment groups, 4.3–18.2% of patients
had ALT levels >3× ULN and 4.3–9.1% had AST levels >3×
ULN at least at one postbaseline measurement. No increases in
either enzyme >3× ULN were seen in PBO or TCZ treated
patients. Neutrophil and leukocyte counts were reduced from
baseline levels in each of the active treatment arms (including
TCZ) from as early as Week 1; the incidence of markedly abnor-
mal neutrophil counts (deﬁned as laboratory values graded 3 or
4 according to the National Cancer Institute Common
Terminology Critera for Adverse Events (CTCAE)) was similar
between OKZ and TCZ treatment groups (range for OKZ: 0–
4.5%; TCZ: 4.7%). There were no incidences of markedly
abnormal leukocyte counts or thrombocytopenia. For the major-
ity of clinical chemistry parameters there were no signiﬁcant dif-
ferences in mean values between PBO, OKZ and TCZ treatment
groups, and no clinically signiﬁcant ﬂuctuations in mean values
over time. One subject in the OKZ 60 mg Q4W group was
found to have elevations in ALT and AST, which was reported as
a serious TEAE. There were four incidences of Grade 3 or 4 ele-
vations in GGT values, and four reports of abnormally high
Grade 3 total cholesterol values, across the OKZ and TCZ
treated patients. All these cases had values that were elevated at
baseline and/or screening, prior to treatment with the study
drug. There was one recorded serious TEAE of increased blood
triglycerides which occurred in the TCZ group.
DISCUSSION
In this Phase II study of patients with RA who had previously
failed TNF inhibitor therapy, treatment with OKZ resulted in sig-
niﬁcantly greater reductions in DAS28(CRP) from baseline levels
at Week 12 compared with treatment with PBO. This improve-
ment was demonstrated at all the OKZ doses tested with gener-
ally comparable efﬁcacy and across both dosing frequencies, and
was statistically signiﬁcant for all dose group comparisons (60,
120 or 240 mg vs PBO). At low OKZ doses, a posthoc analysis
showed greater responses in patients who met the criterion of
high CRP at study entry compared to all other patients.
The primary efﬁcacy endpoint was further supported by the
secondary efﬁcacy variables. Estimated ACR20 and ACR50
response rates at Week 12 were numerically higher in all OKZ
treatment arms than PBO groups, although the study was not
powered to show a statistical difference in the ACR response
rates. Few patients in any treatment group were ACR70 respon-
ders. Comparisons of exploratory efﬁcacy variables, including
health outcomes endpoints generally suggested greater improve-
ment in OKZ treatment groups compared with the PBO groups.
Overall, exploratory comparison showed similar responses to
subcutaneous OKZ treatment and intravenously administered
TCZ across multiple efﬁcacy endpoints and for several OKZ
treatment groups.
Reported TEAEs in this study were consistent with the safety
proﬁle expected of this class of drug, with no new safety signals
Figure 2 Analysis of efﬁcacy endpoints. (A) DAS28(CRP) scorea; (B) DAS28(CRP) change from baseline at Week 12; (C) ACR20 response ratea and
(D) ACR50 response ratea.
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identiﬁed. Commonly reported TEAEs in OKZ treated patients
included gastrointestinal disorders, infections and infestations
(primarily upper and lower respiratory tract infections and
urinary tract infections) and nervous system disorders, which is
qualitatively similar to the safety proﬁle observed for TCZ in
this and other previously published trials, as well as other
anti-IL6 s in development.11 27–31 These TEAEs occurred at
similar frequencies in the PBO, OKZ and TCZ treated groups.
There were no incidences of diverticulitis or gastrointestinal per-
forations reported during the study. In accordance with the role
of IL-6 in immune regulation, inﬂammation and haematopoiesis,
reported TEAEs included increases in AST, ALT and lipids, and
decreases in neutrophil levels. As expected, small increases from
baseline in median total cholesterol, LDL and triglycerides and
decreases in neutrophils were observed in each of the active
treatment arms, including the TCZ group, throughout the
12-week study. No patients fulﬁlled the Hy’s law criteria for
drug-induced liver injury. Most TEAEs were mild to moderate
in nature, with no deaths. In the OKZ and TCZ treatment
groups, there were no opportunistic infections, but two serious
infections (one pneumonia and one abscess reported in patients
treated with each study drug).
Injection site reactions were more commonly reported after
injection with OKZ compared with PBO or TCZ which was
administered intravenously. The highest incidence was reported
in the OKZ 240 mg Q2W group, in accordance with these
patients receiving the greatest number of active subcutaneous
injections. No serious injection site reactions were reported.
The limitations of this study included the small number of
patients in each treatment group and the resultant lack of
statistical power for comparisons beyond the primary endpoint.
This small sample size, along with the heterogeneity of the
study population, resulted in high variability, quantiﬁed by the
PBO groups. Although PBO patients were randomised to
nominal ‘Q4W’ and ‘Q2W’ groups they received identical treat-
ments at all visits and results in these groups (while demonstrat-
ing overall consistency with previous published RA clinical
trials) were variable. Despite this, OKZ across all treatment
groups demonstrated statistically signiﬁcant improvements in the
predeﬁned primary efﬁcacy variable. Graphical comparisons of
different doses and dosing regimens did not reveal signiﬁcant
differences in responses; integration of study data and analysis
using PK/PD methodology revealed dose-exposure-response
relationships for DAS28(CRP) and ACR20 endpoints, albeit
shallow; no signiﬁcant impact of the number of previous failed
treatments with TNF inhibitors could be observed, which may
also be due to small sample sizes. This study used a primary
endpoint of 12 weeks. Study duration is another potential study
limitation given the long half-life of OKZ (31 days19) and the
time required to plateau plasma concentration drug levels.
Additionally, in this study, all patients had previously been
treated with, and failed to respond to, at least one TNF inhibi-
tor, and thus, results seen here may not be directly applicable to
the wider RA population.
In addition to OKZ, several other antibodies targeting the
IL-6 pathway are in development.29–33 Potential differentiating
factors for these antibodies include targeted protein (IL-6 or
IL6R), targeted step of the IL-6 signalling complex cascade,
route of administration, level of humanisation, immunoglobulin
type and/or antibody construct. However, these antibodies are
Table 3 Treatment-emergent adverse events and serious treatment-emergent adverse events (safety set)
MedDRA (V.14.0)
system organ class
Preferred term Dosing frequency
PBO
n/N (%)
OKZ 60 mg
n/N (%)
OKZ 120 mg
n/N (%)
OKZ 240 mg
n/N (%)
TCZ 8 mg/kg
n/N (%)
Any TEAEs Q2W 19/22 (86.4) 14/20 (70.0) 14/22 (63.6) 19/23 (82.6) –
Q4W 17/22 (77.3) 18/22 (81.8) 20/23 (87.0) 19/22 (86.4) 37/43 (86.0)
Gastrointestinal disorders Q2W 7/22 (31.8) 3/20 (15.0) 3/22 (13.6) 5/23 (21.7) –
Q4W 2/22 (9.1) 3/22 (13.6) 4/23 (17.4) 8/22 (36.4) 9/43 (20.9)
General disorders and administration site reactions Q2W 4/22 (18.2) 5/20 (25.0) 5/22 (22.7) 11/23 (47.8) –
Q4W 4/22 (18.2) 9/22 (40.9) 4/23 (17.4) 6/22 (27.3) 9/43 (20.9)
Infections and infestations Q2W 7/22 (31.8) 5/20 (25.0) 6/22 (27.3) 7/23 (30.4) –
Q4W 11/22 (50.0) 6/22 (27.3) 8/23 (34.8) 8/22 (36.4) 16/43 (37.2)
Serious TEAEs Q2W 2 (9.1) 3 (15.0) 0 0 –
Q4W 1 (4.5) 1 (4.5) 0 2 (9.1) 4 (9.3)
Anaemia Q2W 0 0 0 0 –
Q4W 1/22 (4.5) 0 0 0 0
Investigations Q2W 0 0 0 0 –
Q4W 0 1/22 (4.5) 0 0 1/43 (2.3)
Liver function test abnormal Q2W 0 0 0 0 –
Q4W 0 1/22 (4.5) 0 0 0
Blood triglycerides increased Q2W 0 0 0 0 –
Q4W 0 0 0 0 1/43 (2.3)
Infections and infestations Q2W 0 0 0 0 –
Q4W 0 0 0 2/22 (9.1) 2/43 (4.7)
Pneumonia Q2W 0 0 0 0 –
Q4W 0 0 0 1/22 (4.5) 1/43 (2.3)
Neoplasms, benign malignant and unspecified Q2W 0 1/20 (5.0) 0 0 –
Q4W 0 0 0 0 0
Basal cell carcinoma Q2W 0 1/20 (5.0) 0 0 –
Q4W 0 0 0 0 0
Deaths Q2W 0 0 0 0 –
Q4W 0 0 0 0 0
OKZ, olokizumab; PBO, placebo; TCZ, tocilizumab; TEAE, treatment emergent adverse event.
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currently in Phase II or III of clinical development. Thus, the
impact of these factors on efﬁcacy and/or safety has not yet
been fully evaluated.
The data presented here show that in this Phase II trial, OKZ
demonstrated improvements in multiple efﬁcacy variables com-
pared with PBO in patients with moderate-to-severe RA who
had previously failed TNF inhibitor therapy with results com-
parable to TCZ. Additionally, the safety proﬁle following treat-
ment with OKZ at doses up to 240 mg Q2W was in line with
expectations for this class of drug, with a TEAE and laboratory
test proﬁle consistent with the use of IL-6 targeted therapy in
patients with moderate-to-severe RA. Taken together, the results
of this Phase II study are encouraging and support further
studies with OKZ in RA.
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Table 4 Markedly abnormal laboratory values (laboratory values graded 3 or 4 according to CTCAE* V.4.0) (safety set)
MedDRA (V.14.0)
System organ class
preferred term Dosing frequency
PBO
n/N (%)
OKZ 60 mg
n/N (%)
OKZ 120 mg
n/N (%)
OKZ 240 mg
n/N (%)
TCZ 8 mg/kg
n/N (%)
Liver function tests
Alanine aminotransferase increased Q2W 0 0 0 0 –
Q4W 0 1/22 (4.5) 0 0 0
Aspartate aminotransferase increased Q2W 0 0 0 0 –
Q4W 0 1/22 (4.5) 0 0 0
γ glutamyl transferase increased Q2W 0 0 0 0 –
Q4W 0 1/22 (4.5) 0 1/22 (4.5) 1/43 (2.3)
Haematology
Neutrophil count decreased Q2W 0 0 0 0 –
Q4W 0 1/22 (4.5) 0 0 2/43 (4.7)
Leukocyte count decreased Q2W 0 0 0 0 –
Q4W 0 0 0 0 0
Lipids
Total cholesterol increased Q2W 1/22 (4.5) 0 0 1/23 (4.3) –
Q4W 0 1/22 (4.5) 0 1/22 (4.5) 0
Low density lipoprotein increased Q2W 0 0 0 0 –
Q4W 0 0 0 0 0
High density lipoprotein increase Q2W 0 0 0 0 –
Q4W 0 0 0 0 0
Triglycerides increased Q2W 0 0 0 0 –
Q4W 0 0 0 0 0
*National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) V.4. Markedly abnormal values are those graded 3 or 4 and worse than baseline value.
OKZ, olokizumab; PBO, placebo; TCZ, tocilizumab.
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